What BeOne Medicines AG's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 123 | 195 |
| Total trades | 159 | 277 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 277 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Ball Titus B. | Principal Accounting Officer | Sep 01 | Open-market sale · S | −132 | $355.86 | −$47K | 0 |
| Wu Xiaobin | President and COO | Aug 25 | Open-market sale · S | −280 | $380.00 | −$106K | 0 |
| Oyler John | Chief Executive Officer | Aug 12 | Open-market sale · S | −14,102 | $359.12 | −$5.06M | 0 |
| Oyler John | Chief Executive Officer | Aug 12 | Open-market sale · S | −20,899 | $358.41 | −$7.49M | 14,102 |
| Oyler John | Chief Executive Officer | Aug 12 | Open-market sale · S | −15,396 | $357.63 | −$5.51M | 35,001 |
| Oyler John | Chief Executive Officer | Aug 12 | Open-market sale · S | −2,515 | $356.43 | −$896K | 50,397 |
| Oyler John | Chief Executive Officer | Aug 12 | Open-market sale · S | −1,980 | $354.71 | −$702K | 52,912 |
| Oyler John | Chief Executive Officer | Aug 11 | Open-market sale · S | −4 | $367.00 | −$1.47K | 54,892 |
| Oyler John | Chief Executive Officer | Aug 11 | Open-market sale · S | −1,200 | $366.31 | −$440K | 54,896 |
| Oyler John | Chief Executive Officer | Aug 11 | Open-market sale · S | −3,176 | $365.26 | −$1.16M | 56,096 |
| Oyler John | Chief Executive Officer | Aug 11 | Open-market sale · S | −5,211 | $364.31 | −$1.9M | 59,272 |
| Oyler John | Chief Executive Officer | Aug 11 | Open-market sale · S | −13,403 | $363.45 | −$4.87M | 64,483 |
| Oyler John | Chief Executive Officer | Aug 11 | Open-market sale · S | −11,568 | $362.34 | −$4.19M | 77,886 |
| Oyler John | Chief Executive Officer | Aug 11 | Open-market sale · S | −14,569 | $361.47 | −$5.27M | 89,454 |
| Oyler John | Chief Executive Officer | Aug 11 | Open-market sale · S | −8,081 | $360.33 | −$2.91M | 104,023 |
| Oyler John | Chief Executive Officer | Aug 11 | Open-market sale · S | −13,695 | $359.32 | −$4.92M | 112,104 |
| Lee Chan Henry | SVP, General Counsel | Aug 11 | Open-market sale · S | −2,666 | $360.00 | −$960K | 0 |
| Lee Chan Henry | SVP, General Counsel | Aug 11 | Exercise / conversion · M | +796 | $159.03 | +$127K | 2,666 |
| Lee Chan Henry | SVP, General Counsel | Aug 11 | Exercise / conversion · M | +1,058 | $213.32 | +$226K | 1,870 |
| Lee Chan Henry | SVP, General Counsel | Aug 11 | Exercise / conversion · M | +812 | $194.47 | +$158K | 812 |
Loading...